Abstract
Despite many advances achieved to date, heart failure (HF) remains a leading cause of morbidity and mortality. There is a widely-accepted consensus that HF and diabetes are strongly linked by at least 3 mechanisms: associated comorbidities, coronary atherosclerosis or a specific diabetic cardiomiopathy. For the last 2 mechanisms, advanced glycation end-products may contribute to trigger key processes relevant to HF by affecting cardiac function through cross-linking or receptor engagement. This review focuses on the main effects of advanced glycation end-products on cardiomyocytes and endothelial cell function. Some pharmacological approaches are also discussed.
Keywords: Advanced glycation, heart failure, glucose imbalance, diabetes, cardiomyocytes, oxidative stress
Current Vascular Pharmacology
Title: Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Volume: 6 Issue: 1
Author(s): Armando Rojas, Enrique Mercadal, Hector Figueroa and Miguel A. Morales
Affiliation:
Keywords: Advanced glycation, heart failure, glucose imbalance, diabetes, cardiomyocytes, oxidative stress
Abstract: Despite many advances achieved to date, heart failure (HF) remains a leading cause of morbidity and mortality. There is a widely-accepted consensus that HF and diabetes are strongly linked by at least 3 mechanisms: associated comorbidities, coronary atherosclerosis or a specific diabetic cardiomiopathy. For the last 2 mechanisms, advanced glycation end-products may contribute to trigger key processes relevant to HF by affecting cardiac function through cross-linking or receptor engagement. This review focuses on the main effects of advanced glycation end-products on cardiomyocytes and endothelial cell function. Some pharmacological approaches are also discussed.
Export Options
About this article
Cite this article as:
Rojas Armando, Mercadal Enrique, Figueroa Hector and Morales A. Miguel, Advanced Glycation and ROS: A Link between Diabetes and Heart Failure, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331312
DOI https://dx.doi.org/10.2174/157016108783331312 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Current Neuropharmacology Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study
Current Vascular Pharmacology Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery The Emerging Role of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure
Current Pharmaceutical Design Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology A Review of Patent Literature for Iontophoretic Delivery and Devices
Recent Patents on Drug Delivery & Formulation Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
Current Medicinal Chemistry Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools
Current Drug Targets Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection
Current Drug Targets Perspective on ‘Phase V’ or Logistics and Regression as Logical Progression for Community Heart Failure Triage
Current Cardiology Reviews Heart Failure and Cognitive Impairment: Clinical Relevance and Therapeutic Considerations
Current Cardiology Reviews Editorial [Hot Topic: Drug Metabolisms Associated with Human Microbiome (Guest Editor: Chun-Ming Huang) ]
Current Drug Metabolism Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews Optimization of Important Early ADME(T) Parameters of NADPH Oxidase-4 Inhibitor Molecules
Medicinal Chemistry Stem Cells in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology Pharmacogenomics in the Intensive Care Unit: Focus on Potential Implications for Clinical Practice
Recent Patents on Biotechnology Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design